Posttraumatic stress disorder, sleep and medical cannabis treatment: A daily diary study Sharon R. Sznitman, David Meiri, Ben H. Amit, Dennis Rosenberg, Talya Greene Journal of Anxiety Disorders, 2022, 92, 102632 Doi : 10.1016/j.janxdis.2022.102632 Abstract Despite increasing use of Medical Cannabis (MC) among posttraumatic stress disorder(PTSD) patients, research is lacking on how MC treatment relates to PTSD symptomatology, in particular sleep disturbances. This study examines the time gap between MC use and sleep onset and its association with (1) number of awakenings throughout the night, (2) early awakenings, (3) nightmares. Each morning over a two week period, 77 licensed MC patients suffering from PTSD reported [...]
Lire la suiteThe Effects of Cannabinoids on Sleep Bhanu Prakash Kolla, Lisa Hayes, Chaun Cox, Lindy Eatwell, Mark Deyo-Svendsen , and Meghna P. Mansukhani Journal of Primary Care & Community Health, 2022, Volume 13, 1–9. Doi : 10.1177/21501319221081277 Abstract The use of cannabis products to help with sleep and various other medical conditions by the public has increased significantly in recent years. Withdrawal from cannabinoids can lead to sleep disturbance. Here, we describe a patient who developed significant insomnia leading to worsening anxiety, mood, and suicidal ideation in the setting of medical cannabis withdrawal, prompting presentation to the Emergency Department and inpatient admission. There is a limited [...]
Lire la suiteCancer, Cannabis, and the Search for Relief Marcin Chwistek JNCCN—Journal of the National Comprehensive Cancer Network, 2019, Volume 17, Issue 9, 1142-1144. doi : 10.6004/jnccn.2019.7347 “How about medical marijuana?” is a common and often challenging question in oncology clinics today. It is easy to see why. Answering the question is fraught with clinical, legal, and administrative uncertainties. We all want to give patients the best advice, but not much about medical cannabis seems straightforward today. Whatever answer we provide can feel unsatisfactory to patients or ourselves. Answering clinical questions through high-quality research will take many years. And significant political power will be needed to [...]
Lire la suiteMedical cannabis and insomnia in older adults with chronic pain: a cross-sectional study Sharon R. Sznitman, Simon Vulfsons, David Meiri, Galit Weinstein BMJ Supportive & Palliative Care, 2020, 0, 1–6. doi : 10.1136/bmjspcare-2019-001938 Abstract Objectives : Medical cannabis (MC) is increasingly being used for treatment of chronic pain symptoms. Among patients there is also a growing preference for the use of MC to manage sleep problems. The aim of the current study was to examine the associations between use of whole plant cannabis and sleep problems among chronic pain patients. Methods : A total of 128 individuals with chronic pain over the age of 50 years [...]
Lire la suiteAvec le confinement: beaucoup de syndromes de manque Benjamin ROLLAND https://www.addictolyon.fr/post/avec-le-confinement-beaucoup-de-syndromes-de-manque Addictolyon, 19/03/2020, Mis à jour : il y a 4 jours Avec le #confinement lié au #COVID19, les trafics de substances semblent s'être fortement réduits. Résultat: en ville, à l'hôpital, en prison, de nombreux syndromes de manque apparaissent. Afin de faciliter la reconnaissance et la prise en charge des syndrome de sevrage chez les patients, voici un petit document explicatif du repérage et du traitement des syndrome de sevrage à catégories importantes de substance: #tabac, #cannabis, et #opioïdes
Lire la suiteAutorisation Temporaire Exceptionnelle d'Utilisation compassionelle du cannabis médical Laurent Appel (conseil en communication spécialisé en réduction des risques) 06.81.54.10.96 mailto : laurent.appel@asud.org relayé par www.Principesactifs.org, 26/03/2020 La chaine de soins et de médicament est en tension maximum. Le rôle de chacun est de détecter les failles actuelles et surtout futures pour éviter d'ajouter encore de la tension et faire tout sauter.Le cannabis médical peut jouer un rôle majeur tant comme solution thérapeutique alors que qon manque sera un facteur important de tensions. D'un point de vue médical, il va manquer aux patients déjà traités clandestinement et surtout au million de patients en automédication. Nous risquons donc avoir [...]
Lire la suiteCannabis species and cannabinoid concentration preference among sleep-disturbed medicinal cannabis users Katherine A. Belendiuk, Kimberly A. Babson, Ryan Vandrey, Marcel O. Bonn-Miller Addictive Behaviors, 2015, 50, 178–181 doi : 10.1016/j.addbeh.2015.06.032 a b s t r a c t Introduction : Individuals report using cannabis for the promotion of sleep, and the effects of cannabis on sleep may vary by cannabis species. Little research has documented preferences for particular cannabis types or cannabinoid concentrations as a function of use for sleep disturbances. Methods : 163 adults purchasing medical cannabis for a physical or mental health condition at a cannabis dispensary were recruited. They provided self-report of (a)whether [...]
Lire la suiteCannabis, Cannabinoids, and Sleep : a Review of the Literature Kimberly A. Babson, James Sottile, Danielle Morabito Current Psychiatry Reports, 2017, 19, 23 Doi : 10.1007/s11920-017-0775-9 Abstract Purpose of Review : The current review aims to summarize the state of research on cannabis and sleep up to 2014 and to review in detail the literature on cannabis and specific sleep disorders from 2014 to the time of publication. Recent Findings : Preliminary research into cannabis and insomnia suggests that cannabidiol (CBD) may have therapeutic potential for the treatment of insomnia. Delta-9 tetrahydrocannabinol (THC) may decrease sleep latency but could impair sleep quality long-term. Novel studies investigating [...]
Lire la suiteA Cross-Sectional Study of Cannabidiol Users Jamie Corroon and Joy A. Phillips Cannabis and Cannabinoid Research, 2018, 3, 1, 152-161. https://doi.org/10.1089/can.2018.0006 Abstract Introduction: Preclinical and clinical studies suggest that cannabidiol (CBD) found in Cannabis spp. has broad therapeutic value. CBD products can currently be purchased online, over the counter and at Cannabis-specific dispensaries throughout most of the country, despite the fact that CBD is generally deemed a Schedule I controlled substance by the U.S. Drug Enforcement Administration and renounced as a dietary supplement ingredient by the U.S. Food and Drug Administration. Consumer demand for CBD is high and growing, but few studies have examined the [...]
Lire la suite